You can buy or sell LJPC and other stocks, options, ETFs, and crypto commission-free!
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. Read More LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla's investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Yahoo FinanceMay 6
La Jolla Pharmaceutical (LJPC) Reports Q1 Loss, Misses Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 10.69% and -11.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 2
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
The market expects La Jolla Pharmaceutical (LJPC) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
Simply Wall StApr 26
How Should Investors React To La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) CEO Pay?
In 2012 George Tidmarsh was appointed CEO of La Jolla Pharmaceutical Company (NASDAQ:LJPC). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size.
Expected Aug 7, After Hours